Article Details

Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi ...

Retrieved on: 2021-02-01 10:30:00

Tags for this article:

Click the tags to see associated articles and topics

Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi .... View article details on HISWAI: https://www.biospace.com/article/releases/coherus-biosciences-to-expand-late-stage-pipeline-to-immuno-oncology-with-in-license-of-junshi-biosciences-pd-1-toripalimab-in-united-states-and-canada/

Excerpt

Toripalimab is the first Chinese domestic anti-PD-1 monoclonal antibody to obtain a marketing approval in China. More than thirty company-sponsored ...

Article found on: www.biospace.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up